New combo therapy aims to control advanced breast cancer with fewer side effects
NCT ID NCT03264547
Summary
This completed Phase 3 trial tested whether a new drug combination (eribulin + pertuzumab + trastuzumab) could control advanced HER2-positive breast cancer as well as the standard treatment (taxane + pertuzumab + trastuzumab), but with better quality of life. It involved 446 women with advanced or returning breast cancer who hadn't received certain prior chemotherapies. The main goal was to see if the new combination kept the cancer from worsening for a similar length of time while reducing side effects like numbness and tingling.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
Conditions
Explore the condition pages connected to this study.